Continuous manufacturing (CM) has become a contentious topic in the modern pharmaceutical lexicon, driven by divergent ...

With 17 years' experience, Mabion offers an “end-to-end” solution, covering all stages of biologic drug development, from early clone selection and small-scale manufacturing through process ...

DelveInsight's Biologics Drug Substance Manufacturing Market Insights report provides the current and forecast market ...

A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

A PAT roadmap should address data analysis, aggregation, visualization, and the smart utility of those data for greater process understanding.

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

DUBLIN--(BUSINESS WIRE)--The "Biological Drugs - Global Strategic Business ... are allowing for the development of personalized biologics that can modify disease pathways or even repair defective ...

The US Food and Drug Administration (FDA) recently issued its draft guidance, Considerations for the Use of Artificial Intelligence to ...